Valentina Pedoia, Francesco Caliva, Galateia Kazakia, Andrew J Burghardt, Sharmila Majumdar
{"title":"Augmenting Osteoporosis Imaging with Machine Learning.","authors":"Valentina Pedoia, Francesco Caliva, Galateia Kazakia, Andrew J Burghardt, Sharmila Majumdar","doi":"10.1007/s11914-021-00701-y","DOIUrl":"https://doi.org/10.1007/s11914-021-00701-y","url":null,"abstract":"<p><strong>Purpose of review: </strong>In this paper, we discuss how recent advancements in image processing and machine learning (ML) are shaping a new and exciting era for the osteoporosis imaging field. With this paper, we want to give the reader a basic exposure to the ML concepts that are necessary to build effective solutions for image processing and interpretation, while presenting an overview of the state of the art in the application of machine learning techniques for the assessment of bone structure, osteoporosis diagnosis, fracture detection, and risk prediction.</p><p><strong>Recent findings: </strong>ML effort in the osteoporosis imaging field is largely characterized by \"low-cost\" bone quality estimation and osteoporosis diagnosis, fracture detection, and risk prediction, but also automatized and standardized large-scale data analysis and data-driven imaging biomarker discovery. Our effort is not intended to be a systematic review, but an opportunity to review key studies in the recent osteoporosis imaging research landscape with the ultimate goal of discussing specific design choices, giving the reader pointers to possible solutions of regression, segmentation, and classification tasks as well as discussing common mistakes.</p>","PeriodicalId":48750,"journal":{"name":"Current Osteoporosis Reports","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39848273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Peripheral Blood Mononuclear Cells (PBMCs) to Dissect the Underlying Mechanisms of Bone Disease in Chronic Kidney Disease and Rare Renal Diseases.","authors":"Julie Bernardor, Candide Alioli, Marie-Noelle Meaux, Olivier Peyruchaud, Irma Machuca-Gayet, Justine Bacchetta","doi":"10.1007/s11914-021-00707-6","DOIUrl":"https://doi.org/10.1007/s11914-021-00707-6","url":null,"abstract":"<p><strong>Purpose of review: </strong>To describe the methods that can be used to obtain functional and mature osteoclasts from peripheral blood mononuclear cells (PBMCs) and report the data obtained with this model in two peculiar diseases, namely pediatric chronic kidney disease-associated mineral and bone disorders (CKD-MBD) and nephropathic cystinosis. To discuss future research possibilities in the field.</p><p><strong>Recent findings: </strong>Bone tissue undergoes continuous remodeling throughout life to maintain bone architecture; it involves two processes: bone formation and bone resorption with the coordinated activity of osteoblasts, osteoclasts, and osteocytes. Animal models fail to fully explain human bone pathophysiology during chronic kidney disease, mainly due to interspecies differences. The development of in vitro models has permitted to mimic human bone-related diseases as an alternative to in vivo models. Since 1997, osteoclasts have been generated in cell cultures, notably when culturing PBMCs with specific growth factors and cytokines (i.e., M-CSF and RANK-L), without the need for osteoblasts or stromal cells. These models may improve the global understanding of bone pathophysiology. They can be been used not only to evaluate the direct effects of cytokines, hormones, cells, or drugs on bone remodeling during CKD-MBD, but also in peculiar genetic renal diseases inducing specific bone impairment.</p>","PeriodicalId":48750,"journal":{"name":"Current Osteoporosis Reports","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39620100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
V Van Hulten, Nicklas Rasmussen, J H M Driessen, A M Burden, A Kvist, J P van den Bergh
{"title":"Fracture Patterns in Type 1 and Type 2 Diabetes Mellitus: A Narrative Review of Recent Literature.","authors":"V Van Hulten, Nicklas Rasmussen, J H M Driessen, A M Burden, A Kvist, J P van den Bergh","doi":"10.1007/s11914-021-00715-6","DOIUrl":"https://doi.org/10.1007/s11914-021-00715-6","url":null,"abstract":"<p><strong>Purpose of review: </strong>In this narrative review, we have summarized the literature on fracture risk in T1DM and T2DM with a special focus on fracture site, time patterns, glucose-lowering drugs, and micro- and macrovascular complications.</p><p><strong>Recent findings: </strong>T1DM and T2DM were associated with an overall increased fracture risk, with preferent locations at the hip, vertebrae, humerus, and ankle in T1DM and at the hip, vertebrae, and likely humerus, distal forearm, and foot in T2DM. Fracture risk was higher with longer diabetes duration and the presence of micro- and macrovascular complications. In T2DM, fracture risk was higher with use of insulin, sulfonylurea, and thiazolidinediones and lower with metformin use. The increased fracture risk in T1DM and T2DM concerns specific fracture sites, and is higher in subjects with longer diabetes duration, vascular complications, and in T2DM with the use of specific glucose-lowering medication.</p>","PeriodicalId":48750,"journal":{"name":"Current Osteoporosis Reports","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716348/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39620457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"FGF23 and Hypophosphatemic Rickets/Osteomalacia.","authors":"Yuichi Takashi, Daiji Kawanami, Seiji Fukumoto","doi":"10.1007/s11914-021-00709-4","DOIUrl":"https://doi.org/10.1007/s11914-021-00709-4","url":null,"abstract":"<p><strong>Purpose of review: </strong>X-linked hypophosphatemia and tumor-induced osteomalacia are diseases characterized by hypophosphatemia with impaired proximal tubular phosphate reabsorption. Complete resection of responsible tumors is the first-line therapy for patients with tumor-induced osteomalacia. In contrast, phosphate and active vitamin D have been used for patients with X-linked hypophosphatemia and inoperable ones with tumor-induced osteomalacia. The purpose of this review is to summarize the pathogenesis of these diseases and discuss about the new treatment.</p><p><strong>Recent findings: </strong>Excessive FGF23 production has been shown to underline several kinds of hypophosphatemic rickets/osteomalacia including X-linked hypophosphatemia and tumor-induced osteomalacia. Burosumab, an anti-FGF23 monoclonal antibody, was approved for clinical use, while the indications of burosumab are different depending on countries. The inhibition of excessive FGF23 activity has been approved as a new therapy for several kinds of hypophosphatemic diseases. Further studies are necessary to clarify the long-term effects and safety of burosumab.</p>","PeriodicalId":48750,"journal":{"name":"Current Osteoporosis Reports","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39712450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Role of DMP1 in CKD-MBD.","authors":"Aline Martin, Dominik Kentrup","doi":"10.1007/s11914-021-00697-5","DOIUrl":"10.1007/s11914-021-00697-5","url":null,"abstract":"<p><strong>Purpose of review: </strong>Chronic kidney disease-mineral and bone disorder (CKD-MBD) has become a global health crisis with very limited therapeutic options. Dentin matrix protein 1 (DMP1) is a matrix extracellular protein secreted by osteocytes that has generated recent interest for its possible involvement in CKD-MBD pathogenesis. This is a review of DMP1 established regulation and function, and early studies implicating DMP1 in CKD-MBD.</p><p><strong>Recent findings: </strong>Patients and mice with CKD show perturbations of DMP1 expression in bone, associated with impaired osteocyte maturation, mineralization, and increased fibroblast growth factor 23 (FGF23) production. In humans with CKD, low circulating DMP1 levels are independently associated with increased cardiovascular events. We recently showed that DMP1 supplementation lowers circulating FGF23 levels and improves bone mineralization and cardiac outcomes in mice with CKD. Mortality rates are extremely high among patients with CKD and have only marginally improved over decades. Bone disease and FGF23 excess contribute to mortality in CKD by increasing the risk of bone fractures and cardiovascular disease, respectively. Previous studies focused on DMP1 loss-of-function mutations have established its role in the regulation of FGF23 and bone mineralization. Recent studies show that DMP1 supplementation may fill a crucial therapeutic gap by improving bone and cardiac health in CKD.</p>","PeriodicalId":48750,"journal":{"name":"Current Osteoporosis Reports","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11914-021-00697-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39261659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Metabolism in the Tumour-Bone Microenvironment.","authors":"Jessica Whitburn, Claire M Edwards","doi":"10.1007/s11914-021-00695-7","DOIUrl":"10.1007/s11914-021-00695-7","url":null,"abstract":"<p><strong>Purpose of review: </strong>For solid tumours such as breast and prostate cancer, and haematological malignancies such as myeloma, bone represents a supportive home, where the cellular crosstalk is known to underlie both tumour growth and survival, and the development of the associated bone disease. The importance of metabolic reprogramming is becoming increasingly recognised, particularly within cancer biology, enabling tumours to adapt to changing environments and pressures. This review will discuss our current understanding of metabolic requirements and adaptations within the tumour-bone microenvironment.</p><p><strong>Recent findings: </strong>The bone provides a unique metabolic microenvironment, home to highly energy-intensive processes such as bone resorption and bone formation, both of which are dysregulated in the presence of cancer. Approaches such as metabolomics demonstrate metabolic plasticity in patients with advanced disease. Metabolic crosstalk between tumour cells and surrounding stroma supports disease pathogenesis. There is increasing evidence for a key role for metabolic reprogramming within the tumour-bone microenvironment to drive disease progression. As such, understanding these metabolic adaptations should reveal new therapeutic targets and approaches.</p>","PeriodicalId":48750,"journal":{"name":"Current Osteoporosis Reports","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11914-021-00695-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39230711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Poor bone matrix quality: What can be done about it?","authors":"Asier Muñoz, Anxhela Docaj, Maialen Ugarteburu, Alessandra Carriero","doi":"10.1007/s11914-021-00696-6","DOIUrl":"10.1007/s11914-021-00696-6","url":null,"abstract":"<p><strong>Purpose of the review: </strong>Bone's ability to withstand load resisting fracture and adapting to it highly depends on the quality of its matrix and its regulators. This review focuses on the contribution of bone quality to fracture resistance and possible therapeutic targets for skeletal fragility in aging and disease.</p><p><strong>Recent findings: </strong>The highly organized, hierarchical composite structure of bone extracellular matrix together with its (re)modeling mechanisms and microdamage dynamics determines its stiffness, strength, and toughness. Aging and disease affect the biological processes regulating bone quality, thus resulting in defective extracellular matrix and bone fragility. Targeted therapies are being developed to restore bone's mechanical integrity. However, their current limitations include low tissue selectivity and adverse side effects. Biological and mechanical insights into the mechanisms controlling bone quality, together with advances in drug delivery and studies in animal models, will accelerate the development and translation to clinical application of effective targeted-therapeutics for bone fragility.</p>","PeriodicalId":48750,"journal":{"name":"Current Osteoporosis Reports","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11914-021-00696-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39328819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Justin J Tse, Ainsley C J Smith, Michael T Kuczynski, Daphne A Kaketsis, Sarah L Manske
{"title":"Advancements in Osteoporosis Imaging, Screening, and Study of Disease Etiology.","authors":"Justin J Tse, Ainsley C J Smith, Michael T Kuczynski, Daphne A Kaketsis, Sarah L Manske","doi":"10.1007/s11914-021-00699-3","DOIUrl":"10.1007/s11914-021-00699-3","url":null,"abstract":"<p><strong>Purpose of review: </strong>The purpose of this review is to inform researchers and clinicians with the most recent imaging techniques that are employed (1) to opportunistically screen for osteoporosis and (2) to provide a better understanding into the disease etiology of osteoporosis.</p><p><strong>Recent findings: </strong>Phantomless calibration techniques for computed tomography (CT) may pave the way for better opportunistic osteoporosis screening and the retroactive analysis of imaging data. Additionally, hardware advances are enabling new applications of dual-energy CT and cone-beam CT to the study of bone. Advances in MRI sequences are also improving imaging evaluation of bone properties. Finally, the application of image registration techniques is enabling new uses of imaging to investigate soft tissue-bone interactions as well as bone turnover. While DXA remains the most prominent imaging tool for osteoporosis diagnosis, new imaging techniques are becoming more widely available and providing additional information to inform clinical decision-making.</p>","PeriodicalId":48750,"journal":{"name":"Current Osteoporosis Reports","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11914-021-00699-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39208508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lindsay L Loundagain, Todd L Bredbenner, Karl J Jepsen, W Brent Edwards
{"title":"Bringing Mechanical Context to Image-Based Measurements of Bone Integrity.","authors":"Lindsay L Loundagain, Todd L Bredbenner, Karl J Jepsen, W Brent Edwards","doi":"10.1007/s11914-021-00700-z","DOIUrl":"10.1007/s11914-021-00700-z","url":null,"abstract":"<p><strong>Purpose of review: </strong>Image-based measurements of bone integrity are used to estimate failure properties and clinical fracture risk. This paper (1) reviews recent imaging studies that have enhanced our understanding of the mechanical pathways to bone fracture and (2) discusses the influence that inter-individual differences in image-based measurements may have on the clinical assessment of fracture risk RECENT FINDINGS: Increased tissue mineralization is associated with improved bone strength but reduced fracture toughness. Trabecular architecture that is important for fatigue resistance is less important for bone strength. The influence of porosity on bone failure properties is heavily dependent on pore location and size. The interaction of various characteristics, such as bone area and mineral content, can further complicate their influence on bone failure properties. What is beneficial for bone strength is not always beneficial for bone toughness or fatigue resistance. Additionally, given the large amount of imaging data that is clinically available, there is a need to develop effective translational strategies to better interpret non-invasive measurements of bone integrity.</p>","PeriodicalId":48750,"journal":{"name":"Current Osteoporosis Reports","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11914-021-00700-z","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39190967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Julie Kristine Knudsen, Peter Leutscher, Suzette Sørensen
{"title":"Correction to: Gut Microbiota in Bone Health and Diabetes.","authors":"Julie Kristine Knudsen, Peter Leutscher, Suzette Sørensen","doi":"10.1007/s11914-021-00694-8","DOIUrl":"https://doi.org/10.1007/s11914-021-00694-8","url":null,"abstract":"","PeriodicalId":48750,"journal":{"name":"Current Osteoporosis Reports","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11914-021-00694-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39208509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}